MSLN and familial pancreatic carcinoma: A clinical trial in its recruitment phase for investigating the safety, efficacy and tolerability of anti-mesothelin antibody (BMS-986148) in conjunction with anti-PD-1 (nivolumab) in patients with advanced solid tumors including patients with pancreatic cancer (NCT02341625) is underway.